DK1416937T3 - Profylaktisk og terapeutisk anvendelse af hydroxysteroider - Google Patents

Profylaktisk og terapeutisk anvendelse af hydroxysteroider

Info

Publication number
DK1416937T3
DK1416937T3 DK02755176T DK02755176T DK1416937T3 DK 1416937 T3 DK1416937 T3 DK 1416937T3 DK 02755176 T DK02755176 T DK 02755176T DK 02755176 T DK02755176 T DK 02755176T DK 1416937 T3 DK1416937 T3 DK 1416937T3
Authority
DK
Denmark
Prior art keywords
hydroxysteroids
prophylactic
therapeutic use
hydroxy
steroids
Prior art date
Application number
DK02755176T
Other languages
Danish (da)
English (en)
Inventor
Ernst Wuelfert
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Application granted granted Critical
Publication of DK1416937T3 publication Critical patent/DK1416937T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02755176T 2001-08-14 2002-08-13 Profylaktisk og terapeutisk anvendelse af hydroxysteroider DK1416937T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0119810A GB2378898A (en) 2001-08-14 2001-08-14 Prophylactic and therapeutic use of hydroxysteroids
PCT/GB2002/003770 WO2003015791A1 (en) 2001-08-14 2002-08-13 Phophylactic and therapeutic use of hydroxysteroids

Publications (1)

Publication Number Publication Date
DK1416937T3 true DK1416937T3 (da) 2009-08-24

Family

ID=9920376

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02755176T DK1416937T3 (da) 2001-08-14 2002-08-13 Profylaktisk og terapeutisk anvendelse af hydroxysteroider

Country Status (20)

Country Link
US (1) US8148355B2 (ru)
EP (1) EP1416937B1 (ru)
JP (1) JP4541698B2 (ru)
KR (1) KR100895281B1 (ru)
CN (1) CN1700920B (ru)
AT (1) ATE429919T1 (ru)
AU (1) AU2002321472B2 (ru)
CA (1) CA2457050C (ru)
CY (1) CY1109233T1 (ru)
DE (1) DE60232154D1 (ru)
DK (1) DK1416937T3 (ru)
ES (1) ES2324859T3 (ru)
GB (1) GB2378898A (ru)
HK (1) HK1065703A1 (ru)
IL (2) IL160362A0 (ru)
NO (1) NO334819B1 (ru)
NZ (1) NZ531100A (ru)
PT (1) PT1416937E (ru)
RU (1) RU2329049C2 (ru)
WO (1) WO2003015791A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
US7910755B2 (en) 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
EP2147673A1 (en) * 2006-11-30 2010-01-27 Hunter-Fleming Limited Modulation of prostaglandin/cyclooxygenase metabolic pathways
GB0623971D0 (en) * 2006-11-30 2007-01-10 Hunter Fleming Ltd Modulation of prostaglandin/cyclooxygenase metabolic pathways
EP2653163A1 (en) * 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
CN105078954A (zh) * 2015-08-20 2015-11-25 南京华宽信息咨询中心 一种治疗急性肾衰药物及其应用
CN105168197A (zh) * 2015-08-22 2015-12-23 南京华宽信息咨询中心 一种治疗肾功能不全药物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686438A (en) * 1993-03-09 1997-11-11 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
WO1994020111A1 (en) * 1993-03-09 1994-09-15 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5753640A (en) * 1995-06-07 1998-05-19 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5846963A (en) 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
IT1282289B1 (it) * 1995-06-23 1998-03-16 Sigma Tau Ind Farmaceuti 17-idrossiimminoalchil e 17-idrossiimminometilalchenil ciclopentaperidrofenantreni attivi sul sistema cardiovascolare,
CA2302243A1 (en) 1997-08-29 1999-03-11 Dalhousie University Use of polycyclic steroid compounds for the manufacture of a medicament for the treatment of cystic kidney diseases, vascular infarction, uremia and related conditions
AU3467699A (en) * 1998-04-14 1999-11-01 Pharmadigm, Inc. Method for reducing central nervous system impairment
GB0003524D0 (en) * 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363983A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids

Also Published As

Publication number Publication date
JP4541698B2 (ja) 2010-09-08
WO2003015791A1 (en) 2003-02-27
KR100895281B1 (ko) 2009-04-29
US8148355B2 (en) 2012-04-03
DE60232154D1 (de) 2009-06-10
HK1065703A1 (en) 2005-03-04
PT1416937E (pt) 2009-07-24
RU2004104362A (ru) 2005-05-10
CN1700920B (zh) 2012-05-30
IL160362A (en) 2011-10-31
US20040248868A1 (en) 2004-12-09
IL160362A0 (en) 2004-07-25
AU2002321472B2 (en) 2007-11-08
EP1416937A1 (en) 2004-05-12
GB2378898A (en) 2003-02-26
CA2457050A1 (en) 2003-02-27
CY1109233T1 (el) 2014-07-02
JP2005506321A (ja) 2005-03-03
CN1700920A (zh) 2005-11-23
NO20041057L (no) 2004-03-12
ATE429919T1 (de) 2009-05-15
GB0119810D0 (en) 2001-10-10
KR20040041577A (ko) 2004-05-17
NZ531100A (en) 2006-02-24
ES2324859T3 (es) 2009-08-18
CA2457050C (en) 2010-10-12
EP1416937B1 (en) 2009-04-29
NO334819B1 (no) 2014-06-10
RU2329049C2 (ru) 2008-07-20

Similar Documents

Publication Publication Date Title
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO20044054L (no) Administrering av midler for behandling av betennelse
HK1066482A1 (en) Use os fucans in the treatment of adhesions, arthritis and psoriasis
DK0933995T3 (da) Fremgangsmåde til behandling af endotelskader
NO20061911L (no) Immunogene sammensetninger
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
CY1109233T1 (el) Προφυλακτικη και θεραπευτικη χρηση υδροξυστεροειδων
SE9900961D0 (sv) Novel compounds
ATE445389T1 (de) Liposomale glucocorticoide
WO2004054432A3 (en) Methods and devices for therapeutic treatment cardiac and other pathologies
IS7825A (is) Meðferðarfræðileg meðhöndlun
NO20014648L (no) Forbindelser og metoder for behandling av astma, allergi og inflammatoriske sykdommer
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
IL177169A (en) Use of n-(2-aryl- propionyl)-sulfonamides for the preparation of medicaments for the treatment of spinal cord injury
NO20013414L (no) Ny anvendelse av melagatran
HUP0202638A2 (hu) Fermentált búzacsíra-kivonat alkalmazása gyulladáscsökkentő készítmények előállítására
CO5690571A2 (es) Combinacion sinergica que comprende roflumilas y (r,r)-formoterol
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
SI1492521T1 (sl) Kombinirana uporaba l-karnitina, acetil l-karnitina in propil l-karnitina za zdravljenje oligoastenoteratospermije
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
ATE447944T1 (de) Verwendung von formoterol in der prophylaktischen und/oder therapeutischen behandlung von muskelschwund und/oder kachexie-syndrom im zusammenhang mit katabolischen zuständen bei bestimmten krankheiten, wie z.b. krebs, aids, infektionen, diabetes und andere
NO20042586L (no) Behandlingsfremgangsmate
IL172036A0 (en) Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window